Regeneron Announces FDA Has Accepted For Priority Review The Biologics License Application For Odronextamab
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has announced that the FDA has accepted for priority review the Biologics License Application for Odronextamab, a treatment for lymphoma.
September 29, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Odronextamab has been accepted for priority review by the FDA. This could potentially lead to a positive impact on the company's stock in the short term.
The FDA's acceptance for priority review of Regeneron's Odronextamab indicates a positive regulatory development for the company. This could potentially lead to faster approval and market entry of the drug, which would likely have a positive impact on the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100